Circulating miR-25-3p and miR-451a may be potential biomarkers for the diagnosis of papillary thyroid carcinoma

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Li, Min ^a   Song, Qinbin ^a   Li, Hang ^a   Lou, Yi ^a   Wang, Lili ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LET 7I; MICRORNA; MICRORNA 140 3P; MICRORNA 25 3P; MICRORNA 451A; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN25 MICRORNA, HUMAN; MIRN451 MICRORNA, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; THYROID CARCINOMA; THYROID GLAND TISSUE; BLOOD; CARCINOMA; DIFFERENTIAL DIAGNOSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; THYROID NODULE;

BIOMARKERS; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; THYROID NODULE;

EID: 84940758564     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132403     Document Type: Article

References (36)

1. Baldini E, Sorrenti S, Tuccilli C, Prinzi N, Coccaro C, Catania A, et al. Emerging molecular markers for the prognosis of differentiated thyroid cancer patients. Int J Surg. 2014; 12 Suppl 1: S52-56. doi: 10.1016/j.ijsu.2014.05.054 PMID: 24862669
2. Zhang Y, Meng Z, Zhang M, Tan J, Tian W, He X, et al. Immunohistochemical evaluation of midkine and nuclear factor-kappa B as diagnostic biomarkers for papillary thyroid cancer and synchronous metastasis. Life Sci. 2014; 118: 39-45. doi: 10.1016/j.lfs.2014.09.025 PMID: 25283079
3. Sethi K, Sarkar S, Das S, Mohanty B, Mandal M. Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol. 2010; 8: 341-352. PMID: 21222366
4. Tan A, Etit D, Bayol U, Altinel D, Tan S. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol. 2011; 15: 108-116. doi: 10.1016/j.anndiagpath.2010.11.005 PMID: 21315633
5. Fryknas M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, et al. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol. 2006; 27: 211-220. PMID: 16675914
6. Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol. 2010; 21: 80-89. doi: 10.1007/s12022-010-9114-y PMID: 20198455
7. Song Q, Wang D, Lou Y, Li C, Fang C, He X, et al. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol. 2011; 6: 126. doi: 10.1186/1746-1596-6-126 PMID: 22188859
8. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167-1214. doi: 10.1089/thy.2009.0110 PMID: 19860577
9. Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010; 70: 5226-5237. doi: 10.1158/0008-5472.CAN-09-4227 PMID: 20551052
10. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010; 127: 118-126. doi: 10.1002/ijc.25007 PMID: 19876917
11. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102: 19075-19080. PMID: 16365291
12. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006; 13: 497-508. PMID: 16728577
13. Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol. 2007; 18: 163-173. PMID: 18058265
14. Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012; 97: 2084-2092. doi: 10.1210/jc.2011-3059 PMID: 22472564
15. Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A, Gundara JS, Ip JC, et al. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013; 119: 4358-4365. doi: 10.1002/cncr.28254 PMID: 24301304
16. Cantara S, Pilli T, Sebastiani G, Cevenini G, Busonero G, Cardinale S, et al. Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. J Clin Endocrinol Metab. 2014; 99: 4190-4198. doi: 10.1210/jc.2014-1923 PMID: 25057879
17. Zhang J, Liu Y, Liu Z, Wang XM, Yin DT, Zheng LL, et al. Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma. Int J Med Sci. 2013; 10: 585-592. doi: 10.7150/ijms.5794 PMID: 23533107
18. Mehanna HM, Jain A, Morton RP, Watkinson J, Shaha A. Investigating the thyroid nodule. Bmj. 2009; 338: b733. doi: 10.1136/bmj.b733 PMID: 19286747
19. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010; 9: 306. doi: 10.1186/1476-4598-9-306 PMID: 21110877
20. Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol. 2011; 17: 3976-3985. doi: 10.3748/wjg.v17.i35.3976 PMID: 22046085
21. Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y, et al. MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 2010; 1359: 14-21. doi: 10.1016/j.brainres.2010.08.074 PMID: 20816946
22. Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 2012; 106: 740-747. doi: 10.1038/bjc.2011.588 PMID: 22262318
23. Luo J, Zhao Q, Zhang W, Zhang Z, Gao J, Zhang C, et al. A novel panel of microRNAs provides a sensitive and specific tool for the diagnosis of breast cancer. Mol Med Rep. 2014; 10: 785-791. doi: 10.3892/mmr.2014.2274 PMID: 24866395
24. Wang X, Meng X, Li H, Liu W, Shen S, Gao Z. MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer. Clin Transl Oncol. 2014; 16: 954-958. doi: 10.1007/s12094-014-1178-6 PMID: 24696291
25. Xu FX, Su YL, Zhang H, Kong JY, Yu H, Qian BY. Prognostic implications for high expression of MiR-25 in lung adenocarcinomas of female non-smokers. Asian Pac J Cancer Prev. 2014; 15: 1197-1203. PMID: 24606441
26. Zhao H, Wang Y, Yang L, Jiang R, Li W. MiR-25 promotes gastric cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 2014; 385: 207-213. PMID: 24078004
27. Nishida N, Nagahara M, Sato T, Mimori K, Sudo T, Tanaka F, et al. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin Cancer Res. 2012; 18: 3054-3070. doi: 10.1158/1078-0432.CCR-11-1078 PMID: 22452939
28. Razumilava N, Bronk SF, Smoot RL, Fingas CD, Werneburg NW, Roberts LR, et al. miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology. 2012; 55: 465-475. doi: 10.1002/hep.24698 PMID: 21953056
29. Wu C, Wang C, Guan X, Liu Y, Li D, Zhou X, et al. Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma. PLoS One. 2014; 9: e92292. doi: 10.1371/journal.pone.0092292 PMID: 24651474
30. Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y, et al. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis. 2012; 33: 828-834. doi: 10.1093/carcin/bgs030 PMID: 22298638
31. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010; 70: 9798-9807. doi: 10.1158/0008-5472.CAN-10-1001 PMID: 21098710
32. Li Q, Zou C, Zou C, Han Z, Xiao H, Wei H, et al. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett. 2013; 335: 168-174. doi: 10.1016/j.canlet.2013.02.029 PMID: 23435373
33. Wang Z, Zhang H, Zhang P, Li J, Shan Z, Teng W. Upregulation of miR-2861 and miR-451 expression in papillary thyroid carcinoma with lymph node metastasis. Med Oncol. 2013; 30: 577. doi: 10.1007/s12032-013-0577-9 PMID: 23609190
34. Esposito F, Tornincasa M, Pallante P, Federico A, Borbone E, Pierantoni GM, et al. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab. 2012; 97: E710-718. doi: 10.1210/jc.2011-3068 PMID: 22399519
35. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18: 997-1006. doi: 10.1038/cr.2008.282 PMID: 18766170
36. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011; 47: 784-791. doi: 10.1016/j.ejca.2010.10.025 PMID: 21112772